Eicosanoid Pathways Underlying Disease Risk in Pulmonary Arterial Hypertension

Summary

This K08 proposal aims to develop Dr. Mona Alotaibi's scientific and professional skills while investigating the role of metabolic dysregulations and bioactive molecular markers of endothelial dysfunction in pulmonary arterial hypertension (PAH) progression.

What they want

The project will utilize newly developed mass spectrometry approaches, human biosamples, PH murine models, and cell culture experiments to study the role and mechanism of lipoxygenase (LOX)-eicosanoid derangements in PAH. The research hypothesizes that endothelial LOX intermediates contribute to PAH development and progression through sustained pulmonary vasoconstriction and vascular remodeling, particularly via activation of mechano-sensitive and receptor-operated cation channels. Specific aims include determining the relation of LOX-derived eicosanoids with PAH progression and outcomes, examining if LOX-HETEs induce or enhance PH in animal models, and investigating if LOX-HETEs activate or upregulate cation channels in pulmonary arterial vasculature.

Deliverables

Determine the relation of LOX-derived eicosanoids with PAH disease progression and outcomes
Examine whether LOX-HETEs induce spontaneous PAH or enhance PH in animal models
Examine whether LOX-HETEs activate or upregulate mechanosensitive, or receptor operated cation channels in pulmonary arterial vasculature

Technical requirements

Mass spectrometry approaches
Human biosamples
PH murine models
Cell culture experiments

Key personnel

Dr. Mona Alotaibi (candidate)

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.